SCHEMBL51416

SCHEMBL51416

Fc1ccc2ccccc2c1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.60
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
HPRT1 P00492 2/20 0.48
CYP1A2 P05177 2/20 0.46
PAX8 Q06710 1/20 0.43
HIF1A Q16665 1/20 0.42
CYP1B1 Q16678 1/20 0.42
TNF P01375 1/20 0.42
RIPK1 Q13546 1/20 0.42
AR P10275 1/20 0.41
FADS1 O60427 1/20 0.40
LMNA P02545 2/20 0.40
NCEH1 Q6PIU2 1/20 0.40
ITGB2 P05107 1/20 0.40
ICAM1 P05362 1/20 0.40
ITGAL P20701 1/20 0.40
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29870578 1.00 CYP2A6 (0.60) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL22555264 0.94 CYP2A6 (0.54) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL29697719 0.83 CYP2A6 (0.42) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL4650232 0.76 CYP2A6 (0.50) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL30366237 0.75 ALDH1A1 (0.55) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL3836747 0.75 ALDH1A1 (0.55) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL449348 0.75 CYP2A6 (1.00) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL29930545 0.75 ALDH1A1 (0.55) CYP2A6ALDH1A1HSD17B10TSHRTDP1
Ammonia Solution, Strong SCHEMBL11476794 0.73 CYP2A6 (0.95) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL8726153 0.71 CYP2A6 (0.60) CYP2A6ALDH1A1HSD17B10TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117222654-A KRAS G12C inhibitors and uses thereof 苏州赞荣医药科技有限公司 2023-12-12 CN disclosed
CN-113054107-B Organic solution combination for coating organic solar cell 广州追光科技有限公司 2022-10-21 CN disclosed
CN-113054107-A Organic solution combination for coating organic solar cell 广州追光科技有限公司 2021-06-29 CN disclosed
US-10793584-B2 Naphthobischalcogenadiazole derivative and production method therefor OSAKA UNIVERSITY (JP) 2020-10-06 US disclosed
US-20190337966-A1 NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR OSAKA UNIVERSITY (JP) 2019-11-07 US disclosed
US-8129554-B2 Metal complexes MERCK PATENT GMBH (DE) 2012-03-06 US disclosed
US-20090118453-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2009-05-07 US disclosed
US-5114896-A Reaction product of magnesium, halogenated hydrocarbon, alkoxy compound, titanium compound, halogen-containing alcohol and solid halogenated hydrocarbon TONEN CORPORATION (JP) 1992-05-19 US disclosed
EP-0440813-A1 METHOD OF PRODUCING CATALYST COMPONENT FOR OLEFIN POLYMERIZATION Tonen Corporation (JP) 1991-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10793584-B2 Naphthobischalcogenadiazole derivative and production method therefor CYP24A1, CYP26B1, CYP21A2 CYP2A6 96/4885ALDH1A1 600/4885HSD17B10 947/4885
US-20190337966-A1 NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR CYP24A1, CYP26B1, CYP21A2 CYP2A6 96/4885ALDH1A1 600/4885HSD17B10 947/4885
US-20090118453-A1 METAL COMPLEXES SOD1, AP1M1, AP2M1 CYP2A6 2496/4885ALDH1A1 366/4885HSD17B10 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.